scholarly journals Matrix metalloproteinase 2 and 9 enzymatic activities are selectively increased in the myocardium of Chronic Chagas Disease cardiomyopathy patients: role of TIMPs

2021 ◽  
Author(s):  
Monique Andrade Baron ◽  
Ludmila Rodrigues Pinto Ferreira ◽  
Priscila Camillo Teixeira ◽  
Ana Iochabel Soares Moretti ◽  
Ronaldo Honorato Barros Santos ◽  
...  
Keyword(s):  
Dilated Cardiomyopathy ◽  
Chagas Disease ◽  
Idiopathic Dilated Cardiomyopathy ◽  
Matrix Metalloproteinase 2 ◽  
Organ Donors ◽  
Protein Levels ◽  
End Stage ◽  
Chronic Chagas Disease ◽  
Worse Prognosis

Chronic Chagas disease (CCC) is an inflammatory dilated cardiomyopathy with a worse prognosis compared to other cardiomyopathies. We show the expression and activity of Matrix Metalloproteinases (MMP) and of their inhibitors TIMP (tissue inhibitor of metalloproteinases) in myocardial samples of end stage CCC, idiopathic dilated cardiomyopathy (DCM) patients, and from organ donors. Our results showed significantly increased mRNA expression of several MMPs, several TIMPs and EMMPRIN in CCC and DCM samples. MMP-2 and TIMP-2 protein levels were significantly elevated in both sample groups, while MMP-9 protein level was exclusively increased in CCC. MMPs 2 and 9 activities were also exclusively increased in CCC. Results suggest that the balance between proteins that inhibit the MMP-2 and 9 is shifted toward their activation. Inflammation-induced increases in MMP-2 and 9 activity and expression associated with imbalanced TIMP regulation could be related to a more extensive heart remodeling and poorer prognosis in CCC patients.

scholarly journals Measurement of multiple cytokines for discrimination and risk stratification in patients with Chagas’ disease and idiopathic dilated cardiomyopathy

2021 ◽  
Vol 15 (3) ◽  
pp. e0008906
Author(s):  
Yong Wang ◽  
Niels Wessel ◽  
Franziska Kohse ◽  
Adnan Khan ◽  
Heinz-Peter Schultheiss ◽  
...  
Keyword(s):  
Stem Cell ◽  
Growth Factor ◽  
Dilated Cardiomyopathy ◽  
Chagas Disease ◽  
Plasma Concentrations ◽  
Idiopathic Dilated Cardiomyopathy ◽  
Control Group ◽  
High Morbidity ◽  
Inflammatory Processes

Chagas’ disease (CD), caused by the hemoflagellate protozoan, Trypanosoma cruzi, is endemic in most countries of Latin America. Heart failure (HF) is often a late manifestation of chronic CD, and is associated with high morbidity and mortality. Inflammatory processes mediated by cytokines play a key role in the pathogenesis and progression of CD. Keeping in view the inflammatory nature of CD, this study investigated the possible role of 21 different inflammatory cytokines as biomarkers for prediction and prognosis of CD. The plasma concentration of these cytokines was measured in a group of patients with CD (n = 94), and then compared with those measured in patients with dilated cardiomyopathy (DCM) from idiopathic causes (n = 48), and with control subjects (n = 25). Monovariately, plasma levels of cytokines such as stem cell growth factor beta (SCGF beta), hepatocyte growth factor (HGF), monokine induced by interferon gamma (CXCL9), and macrophage inhibitory factor (MIF) were significantly increased in CD patients with advanced HF compared to control group. None of the cytokines could demonstrate any prognostic potency in CD patients, and only MIF and stromal derived factor-1 alpha (CXCL12) showed significance in predicting mortality and necessity for heart transplant in DCM patients. However, multivariate analysis prognosticated a large proportion of CD and DCM patients. In CD patients, HGF and Interleukin-12p40 (IL-12p40) together separated 81.9% of 3-year survivors from the deceased, while in DCM patients, CXCL12, stem cell factor (SCF), and CXCL9 together discriminated 77.1% of survivors from the deceased. The significant increase in plasma concentrations of cytokines such as HGF and CXCL9 in CD patients, and the ability of these cytokines to prognosticate a large proportion of CD and DCM patients multivariately, encourages further studies to clarify the diagnostic and prognostic potential of cytokines in such patients.

The role of dyslipidemia in idiopathic dilated cardiomyopathy

2008 ◽  
Vol 7 ◽  
pp. 29-29
Author(s):  
M SKWAREK ◽  
Z BILINSKA ◽  
L MAZURKIEWICZ ◽  
J GRZYBOWSKI ◽  
M KRUK ◽  
...  
Keyword(s):  
Dilated Cardiomyopathy ◽  
Idiopathic Dilated Cardiomyopathy

scholarly journals Human complement receptor type 1 (CR1) protein levels and genetic variants in chronic Chagas Disease

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Thaisa Lucas Sandri ◽  
Kárita Cláudia Freitas Lidani ◽  
Fabiana Antunes Andrade ◽  
Christian G. Meyer ◽  
Peter G. Kremsner ◽  
...  
Keyword(s):  
Chagas Disease ◽  
Genetic Variants ◽  
Receptor Type ◽  
Complement Receptor ◽  
Human Complement ◽  
Complement Receptor Type ◽  
Protein Levels ◽  
Chronic Chagas Disease ◽  
Complement Receptor Type 1

Surgical therapy for heart failure

2018 ◽  
pp. 157-174
Author(s):  
Stephen Westaby
Keyword(s):  
Heart Failure ◽  
Dilated Cardiomyopathy ◽  
Acute Coronary Syndromes ◽  
Symptomatic Relief ◽  
Left Ventricular ◽  
Idiopathic Dilated Cardiomyopathy ◽  
Coronary Syndromes ◽  
Artery Disease ◽  
End Stage ◽  
Age Range

Congestive heart failure affects 23 million people worldwide, and is the final pathway for many diseases that affect the myocardium. Successful intervention in acute coronary syndromes together with improved management of idiopathic dilated cardiomyopathy and dysrhythmia provide an ever-increasing number of advanced heart failure patients spread over a wide age range. In Western countries, coronary artery disease is responsible for about 70% of patients with idiopathic dilated cardiomyopathy and valvular heart disease accounting for 15%. Since 10% of patients older than 65 years suffer systolic left ventricular dysfunction, the numbers with heart failure will double within the next 25 years. For end-stage patients, cardiac transplantation provides the benchmark for increased longevity and symptomatic relief. However, the vast majority of patients are over 65 years of age or are referred with established comorbidity, which precludes transplantation.

Sign in / Sign up

Export Citation Format

Share Document